34 results about "Lambda-Carrageenan" patented technology

A stabilizer system comprising blends of cellulose, lambda-carrageenan, and guar gum. Food products and beverages, such as energy drinks, are prepared with the stabilizer blends.

A method for manufacturing an antiviral pharmaceutical composition for the prophylaxis or treatment of a rhinovirus infection that includes the utilization of iota-, kappa- or lambda-carrageenan or mixtures thereof.

It is intended to provide a novel system whereby an enteric nutritional supplement or a thickened liquid food can be solidified so that it can be easily administered within a short period of time without liquefying in the body to thereby lighten a care-giver's burden in tube feeding such as gastrostomic feeding. As the results of studies, it is found out that such a nutritional supplement or a thickened liquid food can be quickly thickened or solidified at a temperature of 40 DEG C or below by using a starch adhesive, which contains as the main component sodium iota-carrageenan, sodium kappa-carrageenan, sodium lambda-carrageenan or a mixture thereof, without melting the starch adhesive by heating. Further, it is confirmed that the product is almost free from water liberation when administered from a syringe. That is, use of the above-described carrageenan as a starch adhesive (a semi-solidifying agent) makes it possible to produce the desired semi-solidified enteric nutritional supplement as described above.

Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contain one or more polyanionic microbicides, such as carrageenans, including lambda carrageenan, as well as water-soluble metal salts and specified lectins. Also disclosed are methods for making and using the compositions.

The present invention provides pasty or liquid compositions for applications on mucous membranes of cavities easily reached by hand, having a bio-adhesive prolonged effect or release. The composition includes a polysaccharide matrix agent selected from the group constituting of lambda carrageenan and iota carrageenan. The matrix allows the in situ formation of a matrix film with a reinforced bio-adhesive capacity due to complexation reactions between the polysaccharide matrix agent and the components of the local secretions of the mucous membranes. The compositions can also include a lecithin compound as a reinforcing agent of the intrinsic bio-adhesive properties of the polysaccharide matrix agent. The composition can further include at least one of (a) a hydration medium for the polysaccharide matrix agent, (b) a lecithin co-solvent allowing the dispersion of the micellar lecithin solution in the hydration medium, (c) an additive or additives, and (d) at least one active ingredient.

This invention provides a carrageenan mixture comprising about 60% to about 95% by weight of iota-carrageenans and about 5% to about 25% by weight of lambda-carrageenans, which is useful as an ingredient of a cosmetic formulation such as a fully natural hair styling gel being free from synthetic polymers.

A liquid formulation comprising protein and lambda carrageenan, wherein the lambda carrageenan comprises lambda carrageenan from at least one seaweed of the taxonomic order Halymeniales.

The invention discloses a method for preparing lambda-carrageenan oligosaccharide by carrying out bacterial degradation on lambda-carrageenan degrading bacteria. The method is characterized by comprising the following steps of: firstly, cultivating the lambda-carrageenan degrading bacteria which can generate extracellular lambda-carrageenan degrading enzymes, subsequently directly adding the bacterium liquid into a reaction liquid which contains 0.5-2.0% by weight of the lambda-carrageenan according to a volume ratio of 1:(0.8-1.2), reacting for 1-5 days at 20-30 DEG C under 100-150rpm, centrifuging so as to obtain supernate-containing oligosaccharide, adsorbing the oligosaccharide by using an activated carbon column, desorbing by using 20-40(v)% ethanol, concentrating, freezing and drying so as to obtain the lambda-carrageenan oligosaccharide of which the polymerization degree ranges from 2 to 8. The method has the advantages of being high in preparation process, high in yield, high in stability, and applicable to industrial production, and lambda-carrageenan oligosaccharide of which the polymerization degree ranges from 2 to 8 can be rapidly produced in large scale, so that the method has large application prospects in production of lambda-carrageenan oligosaccharide.

A dentifrice composition which comprises (A) heavy calcium carbonate having a mean particle diameter of 5 to 15 m, (B) water-insoluble inorganic granules having a collapse strength of 10 to 200g / granule, a mean particle diameter of 50 to 150 m, and a difference of 100 m or below between 90% particle diameter and mean particle diameter, and (C) a water-soluble polymeric material comprising at least one member selected from Group (a) and at least one member selected from Group (b) at a (b) / (a) mass ratio of 0.25 to 3, Group (a): sodium alginate, sodium carboxymethylcellulose, methylcellulose, hydroxyethylcellulose, Xanthomonas campestris, lambda-carrageenan, and straight-chain sodium polyacrylate, and Group (b): gellan gum, agar, kappa-carrageenan, iota-carrageenan, gelatin, pectin, and crosslinked sodium polyacrylate, and which has a total content of (a) and (b) of 0.5 to 1.5% by mass based on the whole of the composition.

The invention discloses an application of lambda-carrageenan oligosaccharide to preparation of an anti-rabies virus drug. Experiments prove that the lambda-carrageenan oligosaccharide is low in cytotoxicity so that rabies viruses of various strains can be inhibited on various types of cells and inhibition effect is provided to each stage of the rabies viruses invading the cells; and particularly in the stage after virus adsorption, namely, 12 hours after the cells are infected by the viruses, the lambda-carrageenan oligosaccharide is still capable of remarkably decreasing the rabies virus amount in the cells. According to above discovery, the lambda-carrageenan oligosaccharide can be used as a low-cost effective wound treating agent to replace the anti-rabies virus immune globulin, and has the advantages of decreasing the viruses at the wound part to the greatest extent and reducing the rabies morbidity.